Patterns of breast cancer relapse in accordance to biological subtype
- PMID: 29675790
- DOI: 10.1007/s00432-018-2644-2
Patterns of breast cancer relapse in accordance to biological subtype
Abstract
Purpose: To evaluate the pattern of recurrence of breast cancer according to its biological subtype in a large cohort of patients treated with therapy representative of current practice.
Patients and methods: Patients treated between 2000 and 2016 with known biological subtype were eligible. Data were prospectively collected. Primary endpoint was the subtype-dependent pattern and time of recurrence. Loco-regional and distant site and time of recurrence were assessed.
Results: Median follow-up time was 80.8 months. For 12,053 (82.5%) of 14,595 patients with primary non-metastatic invasive breast cancer a subtype classification was possible. The luminal A subtype had the highest 10-year survival followed by luminal B and luminal/HER2. The worst survival demonstrated HER2 enriched and TNBC. HER2 and TNBC had the highest rate of recurrence in the first 5 years, whereas the rate of recurrence for luminal A and luminal B tumors was initially low, but remained continuously even after 10 years of follow-up. Luminal A tumors demonstrated the lowest rate of distant metastases predominantly in bone. So did luminal B tumors. HER2 enriched subtype was characterized with increased rate of loco-regional recurrence and distant metastases in bone, liver and brain. Luminal/HER2 had pattern of relapse similar to HER2 enriched tumors, with exception of loco-regional relapse and brain metastases. TNBC had higher rate of lung, bone and brain metastases as well as loco-regional relapse.
Conclusion: Breast cancer subtypes are associated with different time and pattern of recurrence and it should be considered during treatment decision.
Keywords: Breast cancer; Metastasis; Recurrence; Subtype.
Similar articles
-
Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.Breast Cancer Res Treat. 2015 May;151(1):183-90. doi: 10.1007/s10549-015-3390-7. Epub 2015 Apr 17. Breast Cancer Res Treat. 2015. PMID: 25893592
-
Outcomes by molecular subtype after accelerated partial breast irradiation using single-entry catheters.Brachytherapy. 2018 Mar-Apr;17(2):415-424. doi: 10.1016/j.brachy.2017.10.009. Epub 2017 Nov 13. Brachytherapy. 2018. PMID: 29146102
-
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.BMC Cancer. 2016 May 12;16:307. doi: 10.1186/s12885-016-2345-7. BMC Cancer. 2016. PMID: 27175930 Free PMC article.
-
How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects.Int J Mol Sci. 2020 Nov 9;21(21):8415. doi: 10.3390/ijms21218415. Int J Mol Sci. 2020. PMID: 33182512 Free PMC article. Review.
-
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.Front Oncol. 2019 Oct 29;9:1124. doi: 10.3389/fonc.2019.01124. eCollection 2019. Front Oncol. 2019. PMID: 31737566 Free PMC article. Review.
Cited by
-
Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases.World J Surg Oncol. 2021 Apr 13;19(1):113. doi: 10.1186/s12957-021-02214-5. World J Surg Oncol. 2021. PMID: 33849563 Free PMC article.
-
How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?Cancers (Basel). 2020 Sep 16;12(9):2638. doi: 10.3390/cancers12092638. Cancers (Basel). 2020. PMID: 32947901 Free PMC article.
-
Characterization of triple negative breast cancer gene expression profiles in Mexican patients.Mol Clin Oncol. 2022 Dec 15;18(1):5. doi: 10.3892/mco.2022.2601. eCollection 2023 Jan. Mol Clin Oncol. 2022. PMID: 36605097 Free PMC article.
-
Relapse-free survival in Sudanese women with non-metastatic breast cancer.Glob Epidemiol. 2022 Sep 8;4:100082. doi: 10.1016/j.gloepi.2022.100082. eCollection 2022 Dec. Glob Epidemiol. 2022. PMID: 37637030 Free PMC article.
-
Correlation between the Warburg effect and progression of triple-negative breast cancer.Front Oncol. 2023 Jan 27;12:1060495. doi: 10.3389/fonc.2022.1060495. eCollection 2022. Front Oncol. 2023. PMID: 36776368 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous